- Report
- July 2025
- 175 Pages
Global
From €4020EUR$4,490USD£3,499GBP
- Clinical Trials
- April 2025
- 115 Pages
Global
From €1791EUR$2,000USD£1,559GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1343EUR$1,500USD£1,169GBP
- Report
- April 2025
- 200 Pages
Global
From €7119EUR$7,950USD£6,196GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2497EUR$2,789USD£2,174GBP
- Report
- May 2022
- 240 Pages
Global
From €2659EUR$2,970USD£2,315GBP
€2955EUR$3,300USD£2,572GBP
- Report
- June 2020
- 753 Pages
Global
From €2659EUR$2,970USD£2,315GBP
€2955EUR$3,300USD£2,572GBP
- Report
- July 2021
- 50 Pages
China
From €2328EUR$2,600USD£2,026GBP
- Report
- May 2024
- 134 Pages
Global
From €5819EUR$6,499USD£5,065GBP
- Report
- August 2025
- 50 Pages
Global
From €2373EUR$2,650USD£2,065GBP
- Report
- November 2021
- 747 Pages
Global
From €3582EUR$4,000USD£3,117GBP
- Book
- February 2018
- 448 Pages
Temozolomide is an alkylating agent used in the treatment of certain types of cancer, most notably glioblastoma multiforme. It is a prodrug, which is converted in the body to its active form, 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC). Temozolomide is used in combination with radiation therapy to treat newly diagnosed glioblastoma multiforme, and as a single agent to treat recurrent glioblastoma multiforme. It is also used to treat anaplastic astrocytoma, a type of brain tumor.
Temozolomide is a generic drug, and is available in many countries. It is marketed by several companies, including Merck, Teva Pharmaceuticals, Mylan, and Sun Pharmaceuticals. Show Less Read more
